Alembic Pharmaceuticals Limited announces USFDA Final Approval for Efinaconazole Topical Solution
Ahmedabad, February 25th: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Efinaconazole Topical Solution, 10%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Jublia Topical Solution,Continue Reading








